Aldeyra Therapeutics (ALDX) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rafael (RFL) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 25.8% versus a loss of 83.1%. Over five years, RFL leads with a -84.2% price change compared with -89.1% for ALDX. Aldeyra Therapeutics is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | RFL |
|---|---|---|
| Share price | $0.84 | $0.9197 |
| Market cap | $50.70M | $47.99M |
| 1-day change | +16.39% | +2.19% |
| YTD return | -83.78% | -22.06% |
| 1-year return | -83.06% | -25.83% |
| 5-year return | -89.06% | -84.19% |
| EPS (TTM) | $-0.31 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $874.00K |
| Revenue growth (YoY) | — | -4.69% |
| Net income (latest FY) | $-33.85M | $-29.64M |
| Operating margin | — | -3822.54% |
| Net margin | — | -3390.73% |
| 52-week high | $5.93 | $3.96 |
| 52-week low | $0.527 | $0.781 |
| Distance from 52-week high | -85.83% | -76.78% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +685.71% | — |
| Average volume | 1.16M | 140.84K |
| Shares outstanding | 60.36M | 51.39M |
| Employees | 6 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed ALDX by 57.2 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ALDX vs RFL FAQ
Which is bigger, Aldeyra Therapeutics or Rafael?
Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $50.70M compared with $47.99M for Rafael (RFL).
Which stock has performed better over the past year, ALDX or RFL?
RFL returned -25.83% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.